COMMON BRAND NAME(S): Xyzal
GENERIC NAME(S): LEVOCETIRIZINE DIHYDROCHLORIDE
Description: Levocetirizine selectively competes w/ histamine for H1-receptor sites on effector cells in the GI tract, blood vessels and resp tract. It is an active isomer of cetirizine.
Onset: W/in 1 hr.
Duration: 24 hr.
Pharmacokinetics:
Absorption: Rapidly and extensively absorbed from the GI tract. High-fat meal reduces peak plasma concentration (approx 36%) and delays time to peak plasma concentration (approx 1.25 hr) but does not affect plasma concentration-time profile. Time to peak plasma concentration: 0.9 hr (tab); 0.5 hr (oral soln).
Distribution: Volume of distribution: 0.4 L/kg. Plasma protein binding: Approx 91-92% (mainly albumin).
Metabolism: Limited metabolism by aromatic oxidation, N- and O-dealkylation, and taurine conjugation.
Excretion: Via urine (85.4%, via glomerular filtration and active tubular secretion) and faeces (12.9%). Plasma half-life: Approx 8-9 hr.